Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.58 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.47 |
| ▸ | CFD | P00746 | 6/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18953154 | 1.00 | P2RX7 (0.58) | P2RX7GID4CFDFPR3FPR2 | |
| SCHEMBL19210755 | 0.94 | GID4 (0.55) | P2RX7GID4CFDFPR3FPR2 | |
| SCHEMBL19233964 | 0.94 | GID4 (0.55) | P2RX7GID4CFDFPR3FPR2 | |
| SCHEMBL30052460 | 0.94 | GID4 (0.55) | P2RX7GID4CFDFPR3FPR2 | |
| SCHEMBL12480517 | 0.86 | P2RX7 (0.55) | P2RX7CFDFPR3FPR2CHRM1 | |
| SCHEMBL17025736 | 0.86 | P2RX7 (0.49) | P2RX7GID4CFDFPR3FPR2 | |
| SCHEMBL17025739 | 0.86 | P2RX7 (0.49) | P2RX7GID4CFDFPR3FPR2 | |
| SCHEMBL19233912 | 0.85 | P2RX7 (0.54) | P2RX7CFDFPR3FPR2CHRM1 | |
| SCHEMBL3163916 | 0.85 | P2RX7 (0.64) | P2RX7CFDFPR3FPR2CHRM1 | |
| SCHEMBL30051988 | 0.83 | P2RX7 (0.51) | P2RX7CFDFPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127366-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-05-02 | — | — | US | disclosed |
| US-20190127366-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-05-02 | — | — | US | disclosed |
| EP-3386504-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017098328-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHAMACEUTICALS, INC. (BB) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017098328-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHAMACEUTICALS, INC. (BB) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127366-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | CFD, CFH, C9 | P2RX7 1940/4885GID4 361/4885CFD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.